Anti-diarrheal medicine effectively managed this symptom in most cases, according to the study report.
Grade 3 diarrhea occurred in 13.4% of patients in the abemaciclib group and 0.4% of patients in the placebo group.
No grade 4 diarrhea was reported.
Grade 3 to 4 neutropenia occurred in 25.5% of patients in the abemaciclib group and 1.7% of patients in the placebo group.
Febrile neutropenia was reported in six patients in the abemaciclib arm.
Evidence (CDK inhibitor therapy after disease progression on a prior CDK inhibitor): The global, double-blind, placebo-controlledpostMONARCHtrial (NCT05169567), reported in abstract form, included 368 patients with HER2-negative ER-positive advanced breast cancer.